BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
BCG-medac Basisdokumentation - medac GmbH
Sie wollen auch ein ePaper? Erhöhen Sie die Reichweite Ihrer Titel.
YUMPU macht aus Druck-PDFs automatisch weboptimierte ePaper, die Google liebt.
64<br />
colombel M, Saint F, chopin D, Malavaud B, Nicolas L, Rischmann P. (2006)<br />
The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial<br />
bladder cancer: results of a randomized, prospective, double-blind, placebo controlled,<br />
multicenter study .<br />
J Urol . Sep;176(3):935-9<br />
coplen D.e., Marcus M.D., Myers J.A., Ratliff t.L., catalona W.J. (1990)<br />
Long term follow up of patients treated with 1 or 2, 6-week courses of intravesical Bacillus<br />
Calmette-Guérin: Analysis of possible predictors of responce free of tumor<br />
J . Urol ., 144 652-657<br />
cookson M.S., Sarosdy M.F. (1992)<br />
Management of Stage T1 Superficial Bladder-Cancer with intravesikal Bacillus-Calmette-<br />
Guérin Therapy<br />
J: Urol:, 148:787-801<br />
crispen R. (1989)<br />
History of <strong>BCG</strong> and ist Substrains .<br />
In EORT Geniourinary Group Monograph 6; <strong>BCG</strong> in Superficial Bladder Cancer . Eds F .M .J .<br />
Debruyne, L . Denis & A .P .M . van der Meijden . New York: Alan R . Liss, Inc . Pp . 53-50<br />
Davis J.W., Sheth S.I., Doviak M.J., Schellhammer P.F. (2002)<br />
Superficial Bladder Carcinoma Treated with Bacillus Calmette-Guérin: Progression-Free<br />
And Desease Specific Survival with Minimum 10-Year follow-up<br />
J . Urol ., 167: 494-501<br />
De Boer e.c., De Jong W.H., Steerenberg P.A., Aarden L.A., tetteroo e., De Groot<br />
e.R., van der Meijden A.P.M., Vegt P.D.J., Debruyne F.M.J., Ruitenberg e.J. (1992a)<br />
Induction of urinary interleukin-I (IL-1), IL-2, IL-6, and tumor necrosis factor during intravesical<br />
immunotherapy with Bacillus Calmette-Guérin in superficial bladder cancer .<br />
Cancer Immunol . Immunother . 34 306-312<br />
De Reijke t.M., de Boer e.c., kurth k.H., Schamhart D.H.J. (1996)<br />
Urinary cytokines during intravesical Bacillus Calmette Guérin therapy for superficial bladder<br />
cancer: processing, stability and prognostic value<br />
J . Urol ., 155: 477-482<br />
De Reijke t.M., de Boer e.c., kurth k.H., Schamhart D.H.J. (1999)<br />
Urinary interleukin-2 monitoring during prolonged Bacillus Calmette-Guérin treatment: can it<br />
predict the optimal naumber of instillations?<br />
J . Urol ., 161: 67-71<br />
DeJager R., Guinan P.D., Lamm D.L., khanna o.P., Brosman S.A., et al. (1991)<br />
Long term complete remission in bladder carcinoma in situ with intravesical Tice Bacillus<br />
Calmette Guérin . Overview analysis of six phase II clinical trials<br />
Urology, 38: 507-513<br />
Donohue J.H., Rosenberg S.A. (1983)<br />
The fate of interleukin 2 after in vivo admistration .<br />
J . immunol ., 130: 2203-22308<br />
Durek c., Rüsch-Gerdes S., Jocham D., Böhle A. (1999)<br />
Interference of Modern Antibacterials with Bacillus Calmette-Guérin Viability<br />
J Urol; 162, 6: 1959-1962<br />
el-Demiry M.I.M., Smith G., Ritchie A.W.S., James cumming J.A., Hargraeve t.B.,<br />
chisholm G.D. (1984)<br />
Local immune responses after intravesical <strong>BCG</strong> treatment for carcinoma in situ<br />
Brit . J . Urol ., 60: 543-548<br />
Freund J. (1956)<br />
The mode of action of immunologic adjuvants<br />
Adv . Tuderc . Res ., 7: 130-148<br />
Gårdmark t, Jahnson S, Wahlquist R, Wijkstrom H, Malmstrom PU. (2007)<br />
Analysis of progression and survival after 10 years of a randomized prospective study comparing<br />
mitomycin-C and bacillus Calmette-Guerin in patients with high-risk bladder cancer .<br />
BJU Int ., 99(4):817-20
Change language